Antiangiogenic VEGF-Ax: A new participant in tumor angiogenesis

Cancer Research

Volumn 75, Issue 14, 2015, Pages 2765-2769

  Eswarappa, Sandeepa M ^a,b   Fox, Paul L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN A RECEPTOR; VASCULOTROPIN AX; VASCULOTROPIN RECEPTOR; ANGIOGENESIS INHIBITOR; ISOPROTEIN; PROTEOME;

ANTIANGIOGENIC ACTIVITY; CANCER RESISTANCE; CANCER THERAPY; COLON CARCINOMA; COLORECTAL CANCER; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TARGETING; DRUG TREATMENT FAILURE; HUMAN; KIDNEY CARCINOMA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; RETINOPATHY; REVIEW; SOLID TUMOR; STOP CODON; TISSUE SPECIFICITY; TRANSLATION REGULATION; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; PROTEIN SYNTHESIS; VASCULARIZATION; VERTEBRATE;

ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN BIOSYNTHESIS; PROTEIN ISOFORMS; PROTEOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VERTEBRATES;

EID: 84942917850     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-3805     Document Type: Review

References (33)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
2. Sitohy B, Nagy JA, Dvorak HF Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res 2012; 72: 1909-14.
3. Ferrara N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 2009; 29: 789-91.
4. Bates DO, Cui TG, Doughty J.M., Winkler M., Sugiono M, Shields JD, et al VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 2002; 62:4123-31.
5. Harper SJ, Bates DO VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer 2008; 8: 880-7.
6. Cromer W, Jennings MH, Odaka Y, Mathis J.M., Alexander JS. Murine rVEGF164b, an inhibitory VEGF reduces VEGF-A-dependent endothelial proliferation and barrier dysfunction. Microcirculation 2010; 17: 536-47.
7. Konopatskaya O, Churchill AJ, Harper S.J., Bates DO, Gardiner TA. VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. Mol Vis 2006; 12: 626-32.
8. Manetti M, Guiducci S, Romano E., Ceccarelli C, Bellando-Randone S, Conforti ML, et al Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis. Circ Res 2011; 109: e14-26.
9. Eswarappa SM, Potdar AA, Koch W.J., Fan Y., Vasu K, Lindner D, et al Programmed translational readthrough generates antiangiogenic VEGF-Ax. Cell 2014; 157: 1605-18.
10. Li GP, Rice CM Mutagenesis of the in-frame opal termination codon preceding nsP4 of Sindbis virus: studies of translational readthrough and its effect on virus replication. J Virol 1989; 63: 1326-37.
11. Houck-Loomis B., Durney MA, Salguero C, Shankar N., Nagle JM, Goff SP, et al. An equilibrium-dependent retroviral mRNA switch regulates translational recoding. Nature 2011; 480: 561-4.
12. Firth AE, Wills NM, Gesteland R.F., Atkins JF. Stimulation of stop codon readthrough: frequent presence of an extended 3'RNA structural element. Nucleic Acids Res 2011; 39: 6679-91.
13. da Silva R.G., Tavora B, Robinson S.D., Reynolds LE, Szekeres C, Lamar J, et al Endothelial alpha3beta1-integrin represses pathological angiogenesis and sustains endothelial-VEGF. Am J Pathol 2010; 177: 1534-48.
14. Lee P, Goishi K, Davidson A.J., Mannix R., Zon L, Klagsbrun M. Neuropilin-1 is required for vascular development and is a mediator of VEGF-dependent angiogenesis in zebrafish. Proc Natl Acad Sci U S A 2002; 99:10470-5.
15. Kawasaki T, Kitsukawa T, Bekku Y., Matsuda Y, Sanbo M, Yagi T., et al. A requirement for neuropilin-1 in embryonic vessel formation. Development 1999; 126: 4895-902.
16. Loenarz C, Sekirnik R, Thalhammer A., Ge W, Spivakovsky E, Mackeen M.M., et al. Hydroxylation of the eukaryotic ribosomal decoding center affects translational accuracy. Proc Natl Acad Sci U S A 2014; 111: 4019-24.
17. Meyer KD, Saletore Y, Zumbo P., Elemento O, Mason CE, Jaffrey SR Comprehensive analysis of mRNA methylation reveals enrichment in 3'UTRs and near stop codons. Cell 2012; 149: 1635-46.
18. Carlile TM, Rojas-Duran MF, Zinshteyn B., Shin H, Bartoli KM, Gilbert WV Pseudouridine profiling reveals regulated mRNA pseudouridylation in yeast and human cells. Nature 2014; 515: 143-6.
19. Fernandez IS, Ng CL, Kelley A.C., Wu G., Yu YT, Ramakrishnan V. Unusual base pairing during the decoding of a stop codon by the ribosome. Nature 2013; 500: 107-10.
20. Geller AI, Rich A. A UGA termination suppression tRNATrp active in rabbit reticulocytes. Nature 1980; 283: 41-6.
21. Yamaguchi Y, Hayashi A, Campagnoni C.W., Kimura A., Inuzuka T, Baba H. L-MPZ, a novel isoform of myelin P0, is produced by stop codon read-through. J Biol Chem 2012; 287: 17765-76.
22. Loughran G, Chou MY, Ivanov I.P., Jungreis I., Kellis M, Kiran AM, et al Evidence of efficient stop codon readthrough in four mammalian genes. Nucleic Acids Res 2014; 42: 8928-38.
23. Schueren F, Lingner T, George R., Hofhuis J, Dickel C, Gartner J., et al. Peroxisomal lactate dehydrogenase is generated by translational read-through in mammals. Elife 2014; 3: e03640.
24. Dunn JG, Foo CK, Belletier N.G., Gavis ER, Weissman JS. Ribosome profiling reveals pervasive and regulated stop codon readthrough in Drosophila melanogaster. Elife 2013; 2: e01179.
25. Guydosh NR, Green R. Dom34 rescues ribosomes in 3' untranslated regions. Cell 2014; 156: 950-62.
26. Beznoskova P, Cuchalova L, Wagner S., Shoemaker CJ, Gunisova S, von der Haar T, et al. Translation initiation factors eIF3 and HCR1 control translation termination and stop codon read-through in yeast cells. PLoS Genet 2013; 9: e1003962.
27. Pujade-Lauraine E., Hilpert F, Weber B., Reuss A, Poveda A, Kristensen G., et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 2014; 32: 1302-8.
28. Bergers G, Hanahan D. Modesofresistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592-603.
29. Hurwitz H, Fehrenbacher L, Novotny W., Cartwright T, Hainsworth J, Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
30. Hayes DF. Bevacizumab treatment for solid tumors: boon or bust? JAMA 2011; 305: 506-8.
31. Carmeliet P, Jain RK Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011; 10: 417-27.
32. Jain RK, Duda DG, Willett C.G., Sahani DV, Zhu AX, Loeffler JS, et al Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009; 6: 327-38.
33. Broll R, Erdmann H, Duchrow M., Oevermann E, Schwandner O, Markert U., et al. Vascular endothelial growth factor (VEGF)-a valuable serum tumour marker in patients with colorectal cancer? Eur J Surg Oncol 2001; 27:37-42.